A Phase I-II Trial of Brentuximab Vedotin Plus Rituximab as Frontline Therapy for Patients with CD30+ and/or EBV+ Lymphomas

Next Previous
Trial Profile

A Phase I-II Trial of Brentuximab Vedotin Plus Rituximab as Frontline Therapy for Patients with CD30+ and/or EBV+ Lymphomas

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Apr 2017

At a glance

  • Drugs Brentuximab vedotin (Primary) ; Rituximab
  • Indications Lymphoma; Lymphoproliferative disorders
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 09 Mar 2013 New trial record
    • 04 Mar 2013 Planned number of patients changed to 33 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top